Scribe Therapeutics Inc. IPO Research Information

Scribe Therapeutics Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Scribe Therapeutics Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Scribe Therapeutics Inc.	SCTX - NASDAQ	$13.00-$15.00	$15.00	$25.00	8.58 million	7/24/2026
Underwriter(s): Leerink Partners, Goldman Sachs, Guggenheim Securities, Wells Fargo
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2026-07-02 Terms Added 2026-07-20

Scribe Therapeutics Inc. Quote & Chart - Click for current quote - SCTX

About Scribe Therapeutics Inc. (adapted from Scribe Therapeutics Inc. prospectus):
They are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "SCTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.